STOCK TITAN

CTNM (NASDAQ: CTNM) insider schedules 4,170-share sale under trading plan

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

An insider of CTNM has filed a notice of intent to sell shares. The filing covers 4,170 shares of common stock to be sold through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $59,964.60 and 23,099,173 shares outstanding.

The shares were originally acquired as 4,170 restricted stock units from the issuer on May 9, 2017. The same account has sold 4,170 shares on December 23, 2025 for $51,009.11 and another 4,170 shares on January 5, 2026 for $43,543.06 under a Rule 10b5‑1 trading plan for Daniel Lorrain.

Positive

  • None.

Negative

  • None.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the CTNM Form 144 filing disclose about upcoming share sales?

The filing discloses an insider’s intent to sell 4,170 common shares of CTNM. These shares are planned to be sold on February 3, 2026 on NASDAQ, with an indicated aggregate market value of $59,964.60.

How many CTNM shares has the insider recently sold under Rule 10b5-1?

The account for Daniel Lorrain sold 4,170 shares on January 5, 2026 for $43,543.06 and another 4,170 shares on December 23, 2025 for $51,009.11 under a Rule 10b5‑1 plan.

How were the CTNM shares in this Form 144 originally acquired?

The 4,170 CTNM shares covered by the notice were acquired as restricted stock units from the issuer. The acquisition occurred on May 9, 2017, and the issuer is shown as the source of the grant in the filing.

What is the total number of CTNM shares outstanding referenced in the filing?

The filing states that there are 23,099,173 common shares of CTNM outstanding. This figure provides context for the planned sale of 4,170 shares, showing the relative size of the insider’s transaction.

Through which broker will the CTNM insider sale be executed?

The planned sale of 4,170 CTNM shares will be handled by Morgan Stanley Smith Barney LLC Executive Financial Services. The filing lists its address as 1 New York Plaza, 8th Floor, New York, NY 10004 for executing the NASDAQ transaction.

What representation does the CTNM insider make about non-public information?

By signing the notice, the person for whose account the CTNM shares are sold represents that they do not know any material adverse nonpublic information about the issuer’s current or prospective operations, consistent with Rule 144 and Rule 10b5‑1 requirements.
Contineum Therapeutics

NASDAQ:CTNM

CTNM Rankings

CTNM Latest News

CTNM Latest SEC Filings

CTNM Stock Data

525.29M
29.39M
1.61%
73.94%
2.21%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN DIEGO